VRNA News and Press, Verona Pharma plc

2024-06-30 09:00:00 ET Summary VRNA received FDA approval for ensifentrine (Ohtuvayre) for the maintenance treatment of COPD on June 26. SNY/REGN's Dupixent represents a potential competitor. As do other drugs in development from SNY/REGN and GSK. Verona has the potential for ...

2024-06-27 07:00:04 ET Raghuram Selvaraju from H.C. Wainwright issued a price target of $36.00 for VRNA on 2024-06-27 06:09:00. The adjusted price target was set to $36.00. At the time of the announcement, VRNA was trading at $14.69. The overall price target consensus is...

2024-06-26 17:34:28 ET More on Verona Pharma Verona Pharma: Next Week's PDUFA Date Ought To Provide An Upside Catalyst Verona Pharma: Key Inflection Point Directly Ahead Verona Pharma plc (VRNA) Q1 2024 Earnings Call Transcript Verona Pharma gets $650M in fin...

Ohtuvayre is indicated for the maintenance treatment of COPD allowing for broad use in COPD patients First inhaled COPD treatment providing bronchodilation and non-steroidal anti-inflammatory effects Conference call tomorrow at 8:30 a.m. EDT / 1:30 p.m. BST LONDON and RALEIG...

2024-06-20 12:45:04 ET Summary Verona Pharma plc's ensifentrine has a PDUFA date on June 26th for COPD treatment, with promising Phase 3 study results suggesting the drug will secure commercial approval. Potential competition from Sanofi / Regeneron's Dupixent poses a threat, but ...

2024-06-15 13:56:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-06-13 10:45:04 ET Micron Technology Inc. (MU) MU is trading UP for the last 5 days, and it at trading at $142.42 with volume of 5,483,382 and a one day change of $1.67 (1.19%). Micron Technology Inc. has a 52-week low of 60.50 and a 52-week high of $141.71. The business's 50-da...

2024-05-28 15:00:05 ET Andrew Tsai from Jefferies issued a price target of $38.00 for VRNA on 2024-05-28 12:40:00. The adjusted price target was set to $38.00. At the time of the announcement, VRNA was trading at $12.5. The overall price target consensus is at $29.83 wit...

2024-05-25 10:24:03 ET More on AbbVie, Amgen, etc. Bristol Myers Squibb: 5.5% Yielder Has Been Crushed In What Could Be A Generational Buying Opportunity Why Gilead Sciences' 4.6% Yield Doesn't Make The Cut For Smart Investors Amgen Stock: Poised To Break Out (Techni...

2024-05-25 00:20:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...